BRCA2 and breast cancer: The KRAS-variant was found in 22.7% (n = 5/22) of patients with two separate primary breast cancers and ovarian cancer; 0% (0/12) of BRCA1 patients, 33.3% (1/3) of BRCA2 patients and 57.1% (4/7) of uninformative patients.